The UK's Shire Pharmaceuticals says that it has received the approval of Health Canada to reintroduce Adderall for the treatment of hyperactivity disorder. Evidence that some patients taking Adderall suffered sudden death and strokes prompted Canadian officials to suspend the drug earlier this year. The FDA limited its response to changing the label for Adderall to warn against its use by adults or children with heart defects.
"Adderall XR is a safe and effective treatment for people diagnosed with Attention Deficit Hyperactivity Disorder, and Shire is very pleased that this medicine will once again be available for patients in Canada," said Shire CEO Matt Emmens.
- read this report from AFX for more